

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



July 15, 2026

Company name: TAUNS Laboratories, Inc.
Representative: Masaki Nonaka, President and CEO
(Code no.: 197A, Standard Market, Tokyo Stock Exchange)
Contact person: Yoshio Uchiyama, Director and CFO
Tel: +81-55-953-9590

Notice of Basic Agreement on Capital and Business Alliance with Splink, Inc.

TAUNS Laboratories, Inc. (headquartered in Izunokuni-shi, Shizuoka, Japan; Masaki Nonaka, President and CEO; Securities Code: 197A; hereinafter “the Company”) hereby announces that it has entered into a strategic partnership with Splink, Inc. (Head Office: MInato-ku, Tokyo; President: Yuki Aoyama; hereinafter “Splink”) and has reached a basic agreement under which TAUNS will subscribe to newly issued common shares of Splink and the two companies will pursue a business alliance aimed at establishing a new dementia care model focused on the early detection and early intervention of dementia, particularly Alzheimer's disease (“AD”).

Strategic Partnership

Splink, inc. × **TAUNS**

**A New Dementia Care Model
Connecting Community-Based
Care with Specialized Care**



1. Background of the Business Alliance


A New Era of Dementia Care Focused on Early Detection and Early Intervention

As Japan's population continues to age rapidly, the number of people living with dementia is expected to increase further, making dementia a major social challenge affecting healthcare, long-term care, and social security systems.

Recent studies suggest that, in addition to managing lifestyle-related diseases such as hypertension and diabetes, appropriate interventions including physical exercise and cognitive activities may help reduce the risk of developing dementia. Consequently, increasing attention is being placed not only on treatment after disease onset but also on interventions during preclinical and early-stage conditions such as Mild Cognitive Impairment (“MCI”) and Subjective Cognitive Decline (“SCD”).

Furthermore, as disease-modifying therapies (“DMTs”) for Alzheimer's disease become increasingly available in clinical practice, identifying patients with Alzheimer's pathology at an early stage and referring them to specialized medical care has become critical for maximizing treatment benefits. During early phases of cognitive decline, including MCI, appropriate interventions such as lifestyle modifications and DMTs may help improve cognitive function or slow disease progression. As a result, evaluating risk and connecting individuals to appropriate interventions at this stage has become an important challenge in dementia care.

However, current dementia risk assessment systems remain insufficient due to shortages of specialists, limited access to advanced diagnostic testing, and the high costs associated with such examinations. Against this backdrop, there is growing demand for simple, objective dementia risk assessment technologies that can be implemented in community-based healthcare settings, including local clinics.



2. Scope of the Business Alliance

(1) Overview

The two companies will collaborate to build a technological foundation for a new dementia care model through a multimodal assessment approach combining digital biomarkers and blood biomarkers.

Splink will provide technologies and platforms for digitally assessing dementia risk, leveraging its expertise in cognitive assessment, AI-based brain image analysis, and implementation know-how across medical institutions and health screening facilities.

TAUNS will contribute its expertise in biomarker research, in-vitro diagnostics (IVD), manufacturing, and quality management to develop blood biomarker-based dementia Point-of-Care Testing (“POCT”) solutions.

By integrating their respective strengths, the companies aim to establish highly accurate and objective dementia risk assessment methods that can be widely implemented in community healthcare settings.

Through this business alliance, TAUNS and PROVIGATE intend to combine PROVIGATE’s GA measurement technology with TAUNS’ proprietary Digital Immunoassay (“D-IA”) technology to develop and offer a home-based blood glucose monitoring POCT** (Point of Care Testing) service targeting the vast global market of people with diabetes and prediabetes.

This service is intended to help individuals monitor their glycemic status conveniently and continuously from home and to facilitate effective behavioral changes that improve health outcomes.

Over the medium to long term, the companies aim to establish this service as a new standard model for home-based monitoring of Type 2 diabetes, while pursuing reimbursement coverage and broader adoption in both domestic and international markets.

Combining the Strengths of Both Companies to Advance Dementia Care through Early Detection and Early Intervention

Turning Suspicion into Confidence

A Game Changer in Dementia



(2) Innovation Targeted Through the Alliance

A New Dementia Risk Assessment Model Combining Digital Technologies and Blood Biomarkers

Age is one of the most significant risk factors for dementia. However, age alone is insufficient to accurately assess an individual's risk.

By integrating multiple sources of information—including cognitive function, brain imaging, and blood biomarkers—a more personalized and comprehensive risk assessment can be achieved.

The companies will develop a multimodal assessment framework combining:


- Demographic information (e.g., age and sex)
- Cognitive function assessment
- MRI image analysis powered by artificial intelligence (AI)
- Blood biomarkers

This integrated approach will enable multidimensional evaluation of dementia risk beyond what any single test can provide.

The companies seek to establish a dementia risk assessment methodology applicable across a broad range of healthcare settings, including:

- Community clinics
- Health screening centers
- Brain health check-up programs ("Brain Dock" services)

Through this effort, they aim to improve both the objectivity and accuracy of dementia risk assessment within community healthcare.



(3) Toward the Realization of a New Dementia Care Model

The two companies will work together to create a new patient pathway that connects early concerns or perceived cognitive changes with appropriate diagnosis and treatment.

Through the use of digital biomarkers and blood biomarkers at local clinics, health screening facilities, and brain health check-up centers, individuals identified as being at elevated risk will be referred to memory clinics and advanced healthcare institutions.

Following comprehensive diagnostic evaluation by specialists, patients can be connected to appropriate interventions including:

- Disease-modifying therapies (DMTs)
- Lifestyle modification programs
- Other early-stage treatment options

This approach is expected to help slow cognitive decline and maintain patients' quality of life (QOL).

By strengthening collaboration between community healthcare providers and specialized medical institutions, the companies aim to establish a healthcare framework that enables more individuals to receive appropriate diagnosis and treatment at the right time.

(4) Expected Social Impact

Through the social implementation of this new dementia care model, Splink and TAUNS aim to contribute to:

- Establishment of early dementia detection systems within community healthcare
- Effective referral of individuals requiring specialized diagnosis and treatment to appropriate medical institutions
- More efficient utilization of limited specialist healthcare resources
- Reduction of regional disparities in dementia care and promotion of more uniform healthcare quality
- Extension of healthy life expectancy

3. Overview of Splink, Inc.

(1) Name	Splink, Inc.
(2) Address	4F, WAW Akasaka, Dai-35 Kowa Building, 1-14-14 Akasaka, Minato-ku, Tokyo, Japan
(3) Title and name of representative	Yuki Aoyama, President
(4) Business	Brain Healthcare Business; Medical Data Platform Business
(5) Date of establishment	January 2017
(6) Corporate site	https://www.splinkns.com

4. Comments from Both Companies

Comment from Masaki Nonaka, President and CEO of TAUNS Laboratories, Inc.

"Under our Mid-Term Management Plan, expansion into the chronic disease field is positioned as one of our key growth strategies. Among these opportunities, we regard dementia as a priority area because it represents a significant social challenge that affects not only patients themselves but also their families and society as a whole.

We are delighted to have reached an agreement to advance a strategic partnership with Splink, a company providing innovative solutions in the dementia field. By combining Splink's cognitive assessment technologies and healthcare AI platform with the dementia POCT solutions currently being developed by TAUNS, we expect to support the realization of early screening and appropriate triage for dementia and mild cognitive impairment in clinical settings.

As the introduction of disease-modifying therapies continues to increase the importance of early detection and intervention, we will work to facilitate closer collaboration between community healthcare providers and specialist institutions, helping more individuals access appropriate diagnosis and treatment at the right time.

Moving forward, we aim to deepen collaboration by leveraging the strengths of both companies to create new value in dementia care, improve patients' quality of life, and contribute to the realization of a sustainable healthcare system."

Comment from Yuki Aoyama, President of Splink, Inc.

"In the field of dementia, the importance of screening and early intervention during the earliest stages, including Mild Cognitive Impairment (MCI), continues to grow. From the perspective of practical implementation, there is a need for testing models that are simple, sustainable, and easily integrated into medical and health screening settings.

Guided by our mission of making brain healthcare a global standard, Splink has developed solutions utilizing cognitive assessment technologies and medical AI. To address these societal challenges, we believe that integrating digital biomarkers with blood biomarker technologies capable of delivering fast and convenient testing at the point of care is essential.

We are encouraged to collaborate with TAUNS, a company with an outstanding track record in infectious disease diagnostics and a strong commitment to expanding into the chronic disease field.

Through this partnership, we aim to combine Splink's cognitive assessment technologies and medical AI with the dementia POCT solutions being developed by TAUNS to create a new screening model that can be implemented not only in community clinics but also in memory clinics.

In addition to Alzheimer's disease, we will also pursue solutions addressing non-Alzheimer's dementias, with the goal of creating patient pathways that connect more individuals to appropriate diagnosis and treatment. By establishing dementia risk assessment methods suitable for community healthcare and guiding those in need toward appropriate care, we will work to accelerate the social implementation of a new dementia care model."

5. Outlook

At this time, the Company believes that the impact of this basic agreement on its near-term financial results will be limited. Should any material impact become evident, the Company will promptly disclose such information.

6. Other Matters

Certain details of this basic agreement have not been disclosed based on mutual agreement between the parties.